ClinicalTrials.gg

Program

KXV01

A development code. Also written as “KXV01 TCR Lentinvivo Injection”.

Its studies are led by TCRx Therapeutics.

Furthest: phase 1, since Jul 22, 20253 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TCRx Therapeutics33 open or runningphase 1since Jul 22, 2025Jul 22, 2025Dec 31, 2026phase 1 · NCT07196579

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2025First study: phase 1 study in Advanced Solid CancerFirst studyNCT07196579 · 30 planned · China
  2. Nov 27, 2025Phase 1 study in Advanced Solid TumorsNCT07275853 · 30 planned · China
  3. May 13, 2026Phase 1 study in Advanced Solid TumorsNCT07596693 · 30 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT07275853
  2. Dec 31, 2026Primary completion: phase 1 study in Advanced Solid CancerNCT07196579
  3. Dec 31, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07596693

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596693Advanced Solid Tumors · China1RecruitingDec 31, 202730
NCT07275853Advanced Solid Tumors · China1RecruitingDec 31, 202630
NCT07196579Advanced Solid Cancer · China1RecruitingDec 31, 202630

How it is read

Names in the registry

  • “KXV01 TCR Lentinvivo Injection”, 3 entries

Codes read as this program: KXV01.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.